Aardvark Therapeutics Q4 and Full Year 2025 Financial Results & Business Update
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results: Key Pipeline and Business Updates
Summary
- Voluntary pause of all clinical trials: Phase 3 HERO and OLE trials for ARD-101 (Prader-Willi Syndrome) and ARD-201 obesity program paused due to unexpected cardiac safety signals.
- Further guidance expected in Q2 2026 for both programs, pending ongoing discussions with the FDA.
- \$110 million in cash and equivalents as of December 31, 2025, supporting operations into Q2 2027.
- Significant increase in R&D and G&A expenses reflecting expanded clinical operations and transition to public company status.
- Publication of positive clinical and preclinical data for ARD-101 in Molecular Metabolism.
Pipeline and Clinical Update: Potentially Price-Sensitive Developments
ARD-101 for Prader-Willi Syndrome (PWS)
-
Voluntary Pause: In February 2026, Aardvark paused enrollment and dosing in the HERO and OLE Phase 3 trials for ARD-101 following unexpected reversible cardiac QRS prolongation observed in a healthy volunteer study (not in PWS patients). This study used a higher dose (1,600 mg twice daily) than employed in PWS trials (800 mg twice daily with dose escalation).
-
Key Safety Findings: Two of eight participants in the healthy volunteer study experienced QRS duration increases >25% from baseline, considered significant. These events were not serious, had no cardiac symptoms, and were reversible upon discontinuation.
-
Follow-On Study: At 800 mg twice daily (no dose escalation), 1 of 23 participants had a transient QRS increase <25%, and another >25%. No serious symptoms; all events reversible. Exposure-response modeling shows 200 mg twice daily yields plasma concentrations below cardiac risk threshold.
-
Next Steps: Comprehensive review underway with the FDA; further guidance on program expected Q2 2026.
ARD-201: Obesity Program (POWER & STRENGTH Trials)
-
Voluntary Pause: All ARD-201 trials, including POWER (combination therapy for prevention of weight regain after GLP-1RA-induced weight loss) and STRENGTH (evaluating weight loss and additive effects with GLP-1RA), have been paused pending review of ARD-101 cardiac safety data.
-
Guidance: Further updates expected Q2 2026.
Clinical & Preclinical Data Publication
-
Positive Data Published: In March 2026, Molecular Metabolism published Phase 2 proof-of-concept results showing ARD-101 (200 mg twice daily) significantly reduced self-reported hunger in obese adults (CoEQ hunger decreased by 1.63 points vs. 0.65 points with placebo).
-
Mechanistic Insights: ARD-101 increased post-dose peptide YY (PYY) and GLP-1, with favorable trends for CCK and reduced ghrelin, suggesting engagement of gut-brain pathways relevant to hunger and hyperphagia.
-
Implication: Data supports continued evaluation of ARD-101 for pathological hunger and hyperphagia, including PWS.
Financial Highlights
- Cash Position: \$110.0 million in cash, cash equivalents, and short-term investments as of December 31, 2025 (up from \$73.7 million in 2024). Projected runway into Q2 2027.
- Research & Development Expenses: Q4 2025: \$14.3 million (vs. \$8.1 million in Q4 2024); FY 2025: \$48.9 million (vs. \$17.4 million in FY 2024). Increase driven by ARD-101 development and personnel costs.
- General & Administrative Expenses: Q4 2025: \$4.4 million (vs. \$1.4 million in Q4 2024); FY 2025: \$13.8 million (vs. \$5.3 million in FY 2024). Increase reflects public company operations, personnel, legal, accounting, and insurance costs.
- Net Loss: Q4 2025 net loss: \$17.6 million (vs. \$8.8 million Q4 2024); FY 2025 net loss: \$57.6 million (vs. \$20.6 million FY 2024).
Balance Sheet Overview
- Total Assets: \$117.2 million as of December 31, 2025 (up from \$77.5 million in 2024).
- Current Liabilities: \$10.5 million (up from \$4.9 million in 2024).
- Stockholders’ Equity: \$106.6 million (up from a deficit of \$54.6 million in 2024, reflecting conversion of preferred stock).
Management Outlook and Forward-Looking Statements
-
Patient Safety Priority: CEO Tien Lee, M.D. emphasized patient safety and the company’s commitment to rapidly resolve clinical pauses with the FDA and resume development as soon as possible.
-
Confidence in ARD-101: Despite cardiac safety observations, management remains confident in ARD-101’s differentiated potential for hyperphagia in PWS, supported by positive clinical data and exposure-response understanding.
-
Risks: Uncertainty around trial resumption, potential delays, and regulatory actions could materially affect future results and share value. The company’s cash runway is subject to change based on operational developments.
Shareholder Considerations & Potential Price Sensitivity
-
Trial Pauses: The voluntary pause of all ARD-101 and ARD-201 clinical trials is highly material, as it delays potential commercialization timelines and could impact Aardvark’s valuation.
-
Regulatory Engagement: Ongoing discussions with the FDA introduce uncertainty; positive resolution may be a future catalyst, while delays or negative findings could significantly impact share price.
-
Cash Position: Strong cash reserves and runway into 2027 provide resilience, but prolonged trial pauses could alter this outlook.
-
Data Publication: The publication of positive clinical results may improve sentiment if safety concerns are resolved.
Contact Information
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties, including regulatory outcomes, trial results, and financial projections. Investors should review all available information and consult their financial advisor before making investment decisions. The author assumes no responsibility for the accuracy of the information or for any actions taken based on this article.
View Aardvark Therapeutics, Inc. Historical chart here
